Printer Friendly

Soluble Expression of Humanized Anti-CD20 Single Chain Antibody in Escherichia coli by Cytoplasmic Chaperones Co-expression.

Introduction

CD20 is a cell surface marker that is expressed on B cell and presented during the stage of pre B cells. CD20 directly converts the phospholipase C-gamma (PLC[gamma]) to active [Ca.sub.2.sup.+] transport pump across the plasma membrane (1). Non Hodgkin Lymphoma (NHL) is one of the malignant diseases that is associated with overexpression of CD20 on B cell surface. Hence, anti-CD20 antibodies are approved as an effective treatment method for targeted therapy of B cell malignancies. Rituximab is an anti-CD20 monoclonal antibody (mAB) (2) that is utilized for treating NHL often culminating in long-lasting response (3). In recent years, various formats of mAb have been developed, such as Fragment antigen-binding (Fab), single chain variable fragments (scFv) and disulfide-stabilized Fv antibody fragment (dsFv). Among them, the scFv format has been extensively studied for various applications (4). Recombinant scFv is generated by joining VH and VL domains through a short polypeptide linker or disulphide bond (5) and Escherichia coli (E. coli) are generally used as host cells (6-8). IBs are composed of proteins with inappropriate structures. To overcome this problem, various strategies have been developed including the use of molecular and chemical chaperones (9, 10).

Molecular chaperones are now well established as cytoplasmic and periplasmic chaperones (11, 12). GroEL, DnaK, GroES, Tig, DnaJ and GrpE are major cytoplasmic chaperones in E. coli. It has been shown that cytoplasmic chaperones inhibit the rate of Inclusion Bodies (IB) formation leading to increase in solubility of recombinant proteins (13, 14). The cytoplasmic chaperones are generally expressed in derivatives of pACYC vector containing chloramphenicol resistance gene (Cmr), araB (ribulokinase) and/or Pztl (Tet) promoters which are inducible with L-Arabinose and Tetracycline, respectively. This article is the first report about the application of chaperone plasmids encoding Gro-EL, DnaJ, Tig, GroES, DnaK and GrpE chaperones to increase the soluble expression of anti-CD20-huscFv in E. coli.

Materials and Methods

Bacterial strains, media, and plasmids

E. coli DH5[alpha], BL21 (DE3) and expression vector pET22b (+) were purchased from Novagen. IPTG, Taq DNA polymerase was obtained from Promega Company. Restriction enzyme and T4 DNA ligase were purchased from Takara Shuzo (Kyoto, Japan). The pUC-57-huscFv construct was obtained from V. Ahmadzadeh (15). The chaperon plasmid set was purchased from TAKARA Bio Inc. (Table 1). Also, the Raji cell line, Ni-NTA resin and protein size marker were obtained from Pasteur Institute of Iran, Qiagen and Fermentas, respectively.

Cloning and expression of humanized single chain antibody

The pUC57 containing target gene (pUC57-hscFv construct) was double digested by restriction enzymes MlsI (MscI) and Xhol (at 5' and 3' ends, respectively). The insert (huscFv) was isolated and subcloned into the pET22b expression vector containing pelB leader sequence to facilitate expression of recombinant protein in the periplasmic space. For confirmation of this recombinant construct (pET22b-huscFv), PCR was used and restriction analysis and sequencing were carried out.

PET-22b-hscFv construct was transformed to BL21 (DE3) and was grown in LB medium complemented with 100 [micro]g [ml.sup.-1] ampicillin. The culture then was incubated with shaking (150 rpm) at 25[degrees]C until culture was induced at [A.sub.600] = 0.7 using 1 mM IPTG for 4, 24 hr. Finally, protein expression was analyzed by 12% SDS-PAGE, followed by visualization with Coomassie Brilliant Blue staining and quantitative analysis by using image processing program called ImageJ (National Institute of Health, Bethesda, MD).

Soluble expression of huscFv by co-expression of pET22b-huscFv with chaperones plasmids

For soluble expression of huscFv, E. coli BL21 (DE3) containing pET22b- huscFv bacterial cells were transformed with various chaperones plasmids. Five chaperones including plasmids pG-KJE8, pGro7, pKj-E7, pG-Tf2 and pTf16 were used. The results from these transformations give the BL21(DE3)/pET22b-huscFv/pG-KJE8, BL21 (DE3)/pET22b-huscFv/pGro7, BL21(DE3)/pET22b-huscFv/pKjE7, BL21(DE3)/pET2 2b-huscFv/pG-Tf2, BL21 (DE3)/pET22b-huscFv/pTf 16. The transformed cells were cultured in 100 ml LB medium containing 20 [micro]g/ml chloramphenicol and 50 [micro]g/ml ampicillin. Induction of cells containing chaperones pGro7, pKjE7 and pG-Tf2 was carried out by L-arabinose, pG-KJE8 by L-arabinose and tetracycline, and pTf16 by tetracycline. For expression of chaperones related inducers, L-arabinose 0.6 mM for pGro7, pKjE7and pTf16, tetracycline 10 ng/ml for pG-Tf2 and both L-arabinose and tetracycline for pG-Tf2 were added into thelOO ml culture medium in the initiation of culture. When the culture OD reached to 0.7, 0.4 mM IPTG was added for induction of huscFv and incubation was continued for 4 hr with shaking (150 rpm) at 30[degrees]C. Then, the cells were harvested by centrifugation at 10000 g for 3 min at room temperature. The cells were resuspended in 10 ml of lysis buffer (100 mM NaCl, 50 mM Na[H.sub.2]P[O.sub.4] at pH=8.0) and were disrupted by sonication (five 30 s pulses interrupted with cooling on ice).

Purification of huscFv

For purification of recombinant protein, the harvested cells were sonicated as described above and soluble part of cells was subjected to affinity chromatography. Briefly, supernatant was applied onto a column containing 2 ml Ni-NTA resin. The column then washed with buffer A (5 mM and 20 mM of imidazole) to remove nonspecific proteins. Finally the sample was eluted by elution buffer containing 250 mM imidazole. The purified recombinant protein was analyzed by 12% SDS-PAGE followed by staining with Coomassie Blue G250. The concentration of purified huscFv was analyzed by nanodrop analyser.

Indirect ELISA for antigen-binding activity of anti-CD20 huscFv

To assay the affinity and determine the antigen binding activity of humanized single chain antibody, the Raji cell lysates ([10.sup.6] cells per ml) were coated in ELISA plates (96-well plate) and incubated overnight at 4[degrees]C After coating, the plates were washed three times with PBS and blocked by 300 [micro]l blocking buffer (PBS buffer containing 3% BSA and 0.05% Tween 20) (PBS-T) for 1 hr at room temperature. In the next step, serial dilutions of soluble huscFv were added to the wells. After washing with PBS-T, 100 [micro] of HRP conjugated protein L (1:3000) were added into the wells, incubated for 1.5 hr at RT, and washed with PBS-T. The reaction was developed with 100 [micro] of TMB at room temperature. Finally, reactions were determined by reading the Optical Density at 450 nm (O[D.sub.450]) to evaluate the affinity of antibodies.

Results

Construction of expression plasmid pET22b-anti-CD20 huscFv

For cloning and expression of anti-CD20 huscFv in E. coli, the pUC57 plasmid containing the gene coding of huscFv was digested with restriction digestion enzymes Mlsl (Mscl) and Xhol and the insert was subcloned into the Mlsl (Mscl) and Xhol site of pET22b (+) expression vector. This subcloning was further confirmed by subsequent restriction digestion analysis (Figure 1).

Expression of recombinant protein

For expression of anti-CD20 huscFv, the BL21 (DE 3) containing ET22b-huscFv was cultured in LB broth containing 100 mg/ml ampicillin. When the cell concentration reached approximately to the OD 600 of 0.7, the culture was induced by addition of 1 Mm IPTG for 4 and 24 hr at 25 [degrees]C. Analysis by SDS-PAGE indicated that anti-CD20 huscFv was efficiently expressed in E. coli with a band of about 28 kDa. Analysis for solubility of recombinant huscFv showed that the majority of huscFv was expressed as IBs (Figure 2).

Soluble expression of huscFv by co-expression of pET22b-huscFv constructs with chaperones plasmids

In order to investigate the contribution of different molecular chaperones in soluble expression of anti-CD20 huscFv in E. coli BL21 (DE3), this anti-CD20 huscFv was co-expressed with different chaperones plasmids. The result indicates that chaperones enhanced soluble expression of huscFv. Co-expression of the huscFv-anti-CD20 with chaperone plasmid sets including pGro7, pG-KJE8, pTf16, pKjE7 and pG-Tf2 indicated enhancement in solubility in comparison to anti-CD20 huscFv that was expressed without the chaperones and the result was analyzed by NanoDrop which is shown in table 2. Importantly, the co-expression of pKJE7 containing GrpE/DnaK/DnaJ has the highest outcome (up to 50%) on soluble expression of recombinant huscFv compared to pGro7, pG-KJE8, pTf16 and pG-Tf2 chaperons (Figure 3).

Purification of huscFv

After cell harvest and lysis by sonication of the cells, soluble fractions were collected by centrifugation at 10000 g for 10 min and recombinant protein was purified by affinity chromatography method from supernatant of E. coli cell lysate. The result showed that purity of the recombinant protein was in high level and determined by SDS-PAGE and seemed as a single band (Figure 4). Afterwards, the concentration of refolded huscFv protein was determined by NanoDrop which is shown in table 2.

ELISA result

ELISA experiments were accomplished with anti-CD20-huscFv. The results demonstrated that huscFv is refolded by pKJE7, pG-KJE8 and pG-Tf2 chaperones had higher binding activity compared to huscFv without chaperone co-expression. On the other hand, the relative ELISA results of huscFv refolded by pGro7 and pTf16 chaperones are similar to huscFv without chaperone co-expression. All of the chaperones, huscFv refolded by pKJE7, revealed the highest binding activity.

Discussion

CD20 antigen expressed on cell surface of immature B cells is a validated target for treatment by anti CD20 mAb, Rituximab. This mAb is a chimeric monoclonal antibody and is approved for treatment of B-cell Non-Hodgkin's Lymphoma (NHL) disease (16).

Due to the size and cost related drawbacks of full length monoclonal antibodies, development of smaller versions of these antibodies using low cost expression system of E. coli is the subject of great interest (17). In spite of low cost and high yield of protein production in E. coli, this expression system suffers from several disadvantages. Expression of eukaryotic proteins in E. coli generally results in production of the recombinant proteins as inclusion body that lack correct 3D structure (18) IBs are composed of proteins with inappropriate structures that are the result of protein expression in non-physiological conditions in the cytoplasm of E. coli. Periplasmic expression is one of strategies to overcome this impediment. Hence, pelB leader peptides were used to allow translocation of unfolded recombinant protein to the oxidizing space of periplasm. The disulphide bonds have an important role in correct folding of recombinant proteins that lead to high stability. So, productions of recombinant proteins in soluble form are the subject of extensive researches. For increasing soluble expression of anti-CD20-huscFv, various approaches are used including co-expression with molecular chaperone, use of chemical chaperones and optimization of the culture conditions. The present study aimed to evaluate the effects of co-expression with different chaperons on soluble expression of recombinant anti-CD20 huscFv (9, 19, 20). For this purpose, the sequence encoding for Rituximab based hscFv was transformed into the BL21 (DE3) for expression.

In our study, partial soluble expression of the huscFv was observed without using any molecular chaperones. Hu X et al indicated that the use of low temperature and low rate of inducer concentration led to enhancement in correct folding and finally increased concentration of soluble and functional form of recombinant proteins (21).

On the other hand, for enhancement of the huscFv soluble expression, various plasmids containing chaperone combinations have been used that revealed remarkable enhancement (up to 50%) of soluble expression in the cytoplasm. The related studies are in agreement with our results (22, 23). Among different chaperone plasmids checked by co-expression, the pKJE7 plasmid set containing DnaK, DnaJ, GrpE chaperone genes demonstrated higher soluble yield in comparison to pGro-7, pG-KJE8, pTf16 and pG-Tf2 plasmids. High level of expression of huscFv with pKJE7 plasmid set depended on close activation between DnaK, DnaJ, GrpE chaperone proteins. The results were in agreement with studies done by Bo et al. They reported that anti-BNP scFv was expressed in soluble form by using pKJE7 plasmid set that has the highest amount of scFv, while increasing expressed soluble form of anti-BNP scFv led to reduction of anti-BNP scFv expression (23). In another study, Heo et al reported the enhancement of soluble expression of anti-c-Met scFv with co-expression of cytoplasmic chaperones (24). On the contrary, Nishihara et al showed that chaperone proteins containing GroEL and GroES have synergic effect with GrpE, DnaK, DnaJ in helping folding an Allergen of Japanese Cedar Pollen, Cryj2, in E. coli (19).

However, in our study, there were not any relative synergistic effects between GroEL and GroES proteins with GrpE, DnaK, DnaJ chaperone proteins. Also, in this study, binding activity of soluble huscFv produced by co-expression of combination of various cytoplasmic chaperones was analyzed by relative ELISA. The result showed that all of the soluble fractions had positive effects in binding activity, among them co-expression with plasmid pKJE7 led to 50% increase in huscFv binding activity compared with and without chaperone coexpression. Increasing the binding activity of huscFv co-expressed with plasmid pKJE7 depended on the absence of both GroELS and DnaKJE. These results indicated that there is not any constructive collaboration between GroELS and DnaKJE. Similar results were previously reported for recombinant protein production in the cytoplasm. Sonoda H et al proved that co-expression of DnaKJE with GroELS has negated the effects of GroELS . Furthermore, Sonoda H et al proved that in the cytoplasmic production system, co-expression of GroES/GroEL displays 4.6 fold evaluation in antigen- binding activity (26).

Conclusion

The result of this study indicates that co-expression of pKJE7 cytoplasmic chaperone with huscFv leads to 50% increase in soluble expression. Furthermore, the result of binding activity revealed that all chaperon plasmids had positive effect in huscFv binding activity. Among them, the maximum huscFv binding activity was obtained when huscFv was co-expressed with pKJE7 plasmid chaperone set.

Acknowledgement

We would like to thank Dr. Kamal Vesissi and Yagoub Safdari for their helpful comments on humanization of anti-CD20 antibody.

Conflict of Interest

The authors declare that they have no competing interests.

Ethical Approval

This article does not contain any studies with human participants or animals performed by any of the authors.

References

(1.) Jazirehi AR. Bonavida B. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan. anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene 2005;24(13):2121-2143.

(2.) Bruggemann M. Winter G. Waldmann H. Neuberger M. The immunogenicity of chimeric antibodies. J Exp Med 1989:170(6):2153-2157.

(3.) Janas E. Priest R. Wilde JI. White JH. Malhotra R. Rituxan (anti-CD20 antibody)-induced translocation of CD20 into lipid rafts is crucial for calcium influx and apoptosis. Clin Exp Immunol 2005;139(3):439-446.

(4.) Pucca MB, Bertolini TB. Barbosa JE. Galina SVR, Porto GS. Therapeutic monoclonal antibodies: scFv patents as a marker of a new class of potential biopharmaceuticals. Braz J Pharm Sci 2011;47(1):31-38.

(5.) Wang R. Xiang S. Feng Y. Srinivas S. Zhang Y. Lin M. et al. Engineering production of functional scFv antibody in E. coli by co-expressing the molecule chaperone Skp. Front Cell Infect Microbiol 2013:3:72.

(6.) Choi JH. Lee SY. Secretory and extracellular pro-duction of recombinant proteins using Escherichia coli. Appl Microbiol Biotechnol 2004:64(5):625-635.

(7.) Sahdev S. Khattar SK. Saini KS. Production of active eukaryotic proteins through bacterial expression systems: a review of the existing biotechnology strategies. Mol Cell Biochem 2008:307(l-2):249-264.

(8.) Terpe K. Overview of bacterial expression systems for heterologous protein production: from molecular and biochemical fundamentals to commercial systems. Appl Microbiol Biotechnol 2006:72(2):211-222. '

(9.) Veisi K. Farajnia S. Zarghami N. Khoram Khorshid HR. Samadi N. Ahdi Khosroshahi S. Zarei Jaliani H. Chaperone-assisted soluble expression of a humanized anti-EGFR ScFv antibody in E. Coli. Adv Pharm Bull 2015: 5(Suppl l):621-627.'

(10.) Welch WJ. Brown CR. Influence of molecular and chemical chaperones on protein folding. Cell Stress Chaperones 1996:1(2):109-115.

(11.) Becker J. Craig EA. Heat-shock proteins as molecular chaperones. Eur J Biochem 1994:219(1-2): 11-23.

(12.) Buchner J. Supervising the fold: functional principles of molecular chaperones. FASEB J 1996:10(1): 10-19.

(13.) Grail N. Livny J, Waldor M, Barel M. Charbit A. Meibom KL. Pivotal role of the Francisella tularensis heat-shock sigma factor RpoH. Microbiology 2009:155(Pt 8): 2560-2572.

(14.) Nishihara K. Kanemori M. Yanagi H. Yura T. Overexpression of trigger factor prevents aggregation of recombinant proteins in Escherichia coli. Appl Environ Microbiol 2000;66(3):884-889.

(15.) Ahmadzadeh V, Farajnia S, Hosseinpour Feizi MA, Khavarinejad RA. Design, expression and characterization of a single chain anti-CD20 antibody; a germline humanized antibody derived from Rituximab. Protein Expr Purif 2014:102:45-51.

(16.) Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003: 22(47):7359-7368.

(17.) Weisser NE. Hall JC. Applications of single-chain variable fragment antibodies in therapeutics and diagnostics. Biotechnol Adv 2009;27(4):502-520.

(18.) Sorensen HP. Mortensen KK. Soluble expression of recombinant proteins in the cytoplasm of Escherichia coli. Microb Cell Fact 2005;4(l):'l.

(19.) Nishihara K. Kanemori M. Kitagawa M. Yanagi H, Yura T. Chaperone coexpression plasmids: differential and synergistic roles of DnaK-DnaJ-GrpE and GroEL-GroES in assisting folding of an allergen of Japanese cedar pollen, Cryj2. in Escherichia coli. Appl Environ Microbiol 1998:64(5):1694-1699.

(20.) Lee KH. Kim HS. Jeong HS, Lee YS. Chaperon in GroESL mediates the protein folding of human liver mitochondrial aldehyde dehydrogenase in Escherichia coli. Biochem Biophys Res Commun 2002;298(2):216-224.

(21.) Hu X. O'Hara L. White S. Magner E. Kane M, Wall JG. Optimisation of production of a domoic acid-binding scFv antibody fragment in Escherichia coli using molecular chaperones and functional immobilisation on a mesoporous silicate support. Protein Expr Purif 2007:52 (1):194-201.

(22.) Shuo-shuo C, Xue-zheng L. Ji-hong S. Effects of co-expression of molecular chaperones on heterologous soluble expression of the cold-active lipase Lip-948. Protein Expr Purif 2011:77(2): 166-172.

(23.) Maeng BH. Nam DH. Kim YH. Coexpression of molecular chaperones to enhance functional expression of anti-BNP scFv in the cytoplasm of Escherichia coli for the detection of B-type natriuretic peptide. World J Microbiol Biotechnol 2011;27(6): 1391 -1398.

(24.) Heo MA. Kim SH. Kim SY. Kim YJ. Chung J, Oh MK. et al. Functional expression of single-chain variable fragment antibody against c-Met in the cytoplasm of Escherichia coli. Protein Expr Purif 2006:47(1):203-209.

(25.) Sonoda H. Kumada Y. Katsuda T. Yamaji H. Functional expression of single-chain Fv antibody in the cytoplasm of Escherichia coli by thioredoxin fusion and co-expression of molecular chaperones. Protein Expr Purif 2010; 70(2):248-253.

(26.) Sonoda H. Kumada Y, Katsuda T. Yamaji H. Cytoplasmic production of soluble and functional single-chain Fv-Fc fusion protein in Escherichia coli. Biochem Eng J 2011;53(3):253-259.

Mohammadreza Vousefi (1, 2), Safar Farajnia (2) (*), Ahad Mobhtarzadeh (1,3), Bahman Ahbari (4), Shiva Ahdi Khosroshahi (5), Mina Mamipour (1), Hassan Dariushnejad (6), and Vahideh Ahmadzadeh (5)

(1.) Department of Biotechnology, Higher Education Institute of Rab-Rashid, Tabriz, Iran

(2.) Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

(3.) Faculty of Medicine, Conabad University of Medical Sciences, Conabad, Iran

(4.) Department of Medical Biotechnology, Faculty of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran

(5.) Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

(6.) Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

(*) Corresponding author:

Safar Farajnia, Ph.D., Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

Tel: +98 9143018589

Fax: +98 41 33363231

E-mail:

farajnias@tbzmed.ac.ir

Received: 24 lan 2017

Accepted: 27 May 2017
Table 1 The detailed characteristics of plasmids used in the present
study

Plasmid      Proteins                    Drug resistance marker

pUC57        hscFv-antiCD20              Amp
pET22b(+)    hscFv-antiCD20              Amp
pG-KJE8      dnaK-dnaJ-grpE-groES-groEL  Cm
pGro7        groES-groEL                 I'm
pKjE7        DnaK-dnaJ-grpE              Cm
pTf16        groES-groEL-tig             Cm
pG-Tf2       tig                         Cm

Plasmid      Promoter  Inducer      Reference

pUC57        lac       IPTG         [15]
pET22b(+)    T7        IPTG         This study
pG-KJE8      araB      L-Arabinose
             Pztl      Tetracyclin  (Takara. Japan)
pGro7        araB      L-Arabinose  (Takara. Japan)
pKjE7        araB      L-Arabinose  (Takara. Japan)
pTf16        Pztl      Tetracyclin  (Takara. Japan)
pG-Tf2       araB      L-Arabinose  (Takara, Japan)

Table 2. Comparison of plasmids relative activity with different
expression levels of huscFv

                  Concentration of  Concentration of  The quantity of
Plasmid           insoluble huscFv  soluble huscFv   resultant refolded
                  ([micro]g/mI)     ([micro]g/ml)     huscFv ([micro]g)

huscFv-antiCD20   43.15             164                82
huscFv + pG-KJE8  64.12              51 31            256.5
huscFv + pG-Tf2   76.47              42.76            213.8
huscFv + pKJE7    76.51              65.13            325.65
huscFv + pGro7    52.41              34.26            171.3
huscFv + pTf16    53.70              27.2             136

Plasmid           The ratio of solubility  The ratio of insolubility in
                  in total huscFv (%)      total huscFv (%)

huscFv-antiCD20   27.53                    72.47
huscFv + pG-KJE8  44.45                    55.55
huscFv + pG-Tf2   35.86                    64.14
huscFv + pKJE7    45.98                    54.02
huscFv + pGro7    39.52                    60.48
huscFv + pTf16    33.62                    66.38
COPYRIGHT 2018 Avicenna Research Institute
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Original Article
Author:Vousefi, Mohammadreza; Farajnia, Safar; Mobhtarzadeh, Ahad; Ahbari, Bahman; Khosroshahi, Shiva Ahdi;
Publication:Avicenna Journal of Medical Biotechnology (AJMB)
Article Type:Report
Date:Jul 1, 2018
Words:3413
Previous Article:LACK Gene's Immune Response Induced by Cocktail DNA Vaccine with IL-12 Gene Against Cutaneous Leishmaniasis in BALB/c Mice.
Next Article:A Feasibility Study to Evaluate Bacillus subtilisas a Host for Producing Recombinant Human Parathyroid Hormone.
Topics:

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |